亚盛医药(06855)发布公告,受托人于2025年4月8日根据2022年受限制股份单位计划目的,购买了合共5万股现有股份。这些股份占公司在公告日期已发行股份总数的约0.014%。此次购买的总代价为176万港元,平均每股购买价格约为35.2港元。公告中提到,受托人持有的股份总数目前为217万股,均根据2022年受限制股份单位计划的规则及与受托人订立的信托契约持有。需要注意的是,受托人不能行使其持有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.